Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.24 | -$0.22 | -$0.23 |
| Q2 2026 | 2 | -$0.20 | -$0.18 | -$0.19 |
| Q3 2026 | 1 | -$0.18 | -$0.16 | -$0.16 |
| Q4 2026 | 1 | -$0.17 | -$0.16 | -$0.16 |
| Q1 2027 | 1 | -$0.18 | -$0.16 | -$0.17 |
| Q2 2027 | 1 | -$0.13 | -$0.11 | -$0.12 |
| Q3 2027 | 1 | -$0.10 | -$0.09 | -$0.09 |
| Q4 2027 | 1 | -$0.10 | -$0.09 | -$0.09 |
Exagen Inc last posted its earnings results on Tuesday, March 10th, 2026. The company reported $-0.2 earnings per share for the quarter, missing analysts' consensus estimates of $-0.2 by $0. The company had revenue of 16.63 M for the quarter and had revenue of 66.58 M for the year. Exagen Inc has generated $-1 earnings per share over the last year ($-0.93 diluted earnings per share) and currently has a price-to-earnings ratio of -3.31. Exagen Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/10/2026 | Q4 2025 | -$0.20 | -$0.21 | -0.01 | $16.57 M | $16.63 M |
| 11/04/2025 | Q3 2025 | -$0.13 | -$0.31 | -0.18 | $16.88 M | $17.24 M |
| 07/29/2025 | Q2 2025 | -$0.18 | -$0.21 | -0.03 | $16.31 M | $17.20 M |
| 05/05/2025 | Q1 2025 | -$0.20 | -$0.20 | 0 | $14.55 M | $15.50 M |
| 03/11/2025 | Q4 2024 | -$0.27 | -$0.20 | 0.07 | $13.59 M | $13.66 M |
| 11/12/2024 | Q3 2024 | -$0.30 | -$0.28 | 0.02 | $13.57 M | $12.51 M |
| 08/05/2024 | Q2 2024 | -$0.36 | -$0.16 | 0.2 | $13.13 M | $15.06 M |
| 05/13/2024 | Q1 2024 | -$0.40 | -$0.19 | 0.21 | $13.09 M | $14.42 M |
| 03/18/2024 | Q4 2023 | -$0.41 | -$0.31 | 0.1 | N/A | $13.77 M |
| 11/13/2023 | Q3 2023 | -$0.50 | -$0.31 | 0.19 | N/A | $13.42 M |
| 08/07/2023 | Q2 2023 | -$0.48 | -$0.28 | 0.2 | N/A | $14.14 M |
| 05/15/2023 | Q1 2023 | -$0.52 | -$0.44 | 0.08 | N/A | $11.23 M |
| 03/20/2023 | Q4 2022 | -$0.71 | -$0.83 | -0.12 | N/A | $12.84 M |
| 11/21/2022 | Q3 2022 | N/A | -$0.47 | N/A | N/A | $14.73 M |
| 08/04/2022 | Q2 2022 | -$0.55 | -$0.86 | -0.31 | N/A | $7.61 M |
| 05/11/2022 | Q1 2022 | -$0.59 | -$0.60 | -0.01 | N/A | $10.39 M |
| 03/22/2022 | Q4 2021 | -$0.49 | -$0.42 | 0.07 | N/A | $12.69 M |
| 11/10/2021 | Q3 2021 | -$0.43 | -$0.42 | 0.01 | N/A | $12.25 M |
| 08/09/2021 | Q2 2021 | -$0.50 | -$0.38 | 0.12 | N/A | $12.77 M |
| 05/11/2021 | Q1 2021 | -$0.46 | -$0.48 | -0.02 | N/A | $10.59 M |
The conference call for Exagen Inc's latest earnings report can be listened to online.
The conference call transcript for Exagen Inc's latest earnings report can be read online.
Exagen Inc (:XGN) has a recorded annual revenue of $66.58 M.
Exagen Inc (:XGN) has a recorded net income of $-19,951,000.Exagen Inc has generated $-0.93 earnings per share over the last four quarters.
Exagen Inc (:XGN) has a price-to-earnings ratio of -3.31 and price/earnings-to-growth ratio is 0.3.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED